Építés alatt – nem éles oldal
Belépés

NCT07632677Toboroz

Diagnostic Value of the Liver Inflammation Index for MASH in Patients With T2DM and MAFLD

A Multicenter Cross-Sectional Study Evaluating the Diagnostic Accuracy of the Liver Inflammation Index for Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Patients With Concurrent Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Fatty Liver Disease

Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. jún. 8.

Következő lépések

Rövid összefoglaló (regiszter, angolul)

This observational study aims to evaluate a new diagnostic tool, the Liver Inflammation Index, in detecting Metabolic Dysfunction-Associated Steatohepatitis (MASH) among adults who have both Type 2 Diabetes Mellitus (T2DM) and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).

Állapot (regiszter)
Toboroz
Vizsgálattípus
Megfigyeléses
Résztvevők száma
10000 (tervezett)
Első benyújtás
2026. máj. 23.
Kezdés
2026. máj. 15.
Elsődleges befejezés
2027. dec. 31.
Fő szponzor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
NCT-szám
NCT07632677

Mit vállalsz

  • Vizsgálat típusa: Megfigyeléses
  • Tervezett résztvevők: 10000
  • 2026. máj. 15. és az elsődleges befejezés (2027. dec. 31.) között
  • 22 helyszín, 1 országban
  • Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket

A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.

Ki nem vehet részt

Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

Más betegség

  • Presence of unhealed wounds, scars, or other conditions in the right upper abdominal region that are unsuitable for ultrasonographic examination;
  • Development of other liver diseases during follow-up, including viral hepatitis, drug-induced liver injury, autoimmune liver disease, alcoholic liver disease, or other chronic liver diseases;
  • History of hepatic decompensation;
  • History of hepatectomy or liver transplantation;
  • History of other malignancies;
  • Presence of vascular liver disease, cystic fibrosis-associated liver disease, sarcoidosis, polycystic liver disease, congenital or rare hereditary liver diseases, mechanical cholestasis, secondary sclerosing cholangitis, or heart failure accompanied by hepatic venous congestion;
  • History of transjugular intrahepatic portosystemic shunt (TIPS);
  • Occurrence of acute hepatitis during follow-up (defined as alanine aminotransferase levels >5 times the upper limit of normal) or acute-on-chronic liver failure (ACLF);

Egyéb

  • Clinical or subclinical hypothyroidism or hyperthyroidism.

Kiket keres a vizsgálat

  • Adults aged ≥18 years, with no restrictions on sex;
  • Patients clinically diagnosed with metabolic dysfunction-associated fatty liver disease (MAFLD) according to the Chinese Society of Hepatology guideline Guidelines for the Prevention and Treatment of Metabolic Dysfunction-Associated (Nonalcoholic) Fatty Liver Disease (2024 Edition), and additionally diagnosed with type 2 diabetes mellitus (T2DM) based on the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes Mellitus (2024 Edition).

Életkor a regiszterben: 18 év – - · Nem: nők és férfiak · Egészséges önkénteseket nem fogad

A teljes feltétellista: ClinicalTrials.gov

Helyszínek (22)

Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.

HelyszínVárosOrszágHelyszín állapota
Department of Endocrinology, the First Affiliated Hospital of Bengbu Medical UniversityBengbuKínaToboroz
Department of Endocrinology, Zhujiang Hospital, Southern Medical UniversityGuangzhouKínaToboroz
Department of Obesity and Metabolic Diseases, Panyu Hospital of Traditional Chinese MedicineGuangzhouKínaToboroz
Department of Endocrinology, Hainan General HospitalHaikouKínaToboroz
Department of Endocrinology, Sir Run Run Shaw Hospital, Zhejiang University School of MedicineHangzhouKínaToboroz
Department of Endocrinology, the Second Affiliated Hospital of Anhui Medical UniversityHefeiKínaToboroz
Department of Endocrinology, the First Affiliated Hospital of University of South ChinaHengyangKínaToboroz
Department of Endocrinology, the Third People's Hospital of Yunnan ProvinceKunmingKínaToboroz
Department of Endocrinology, Endocrine and Metabolic Disease Medical Center,Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing UniversityNanjingKínaToboroz
Department of Endocrinology, the First Affiliated Hospital of Guangxi Medical UniversityNanningKínaToboroz
Department of Endocrinology, the Affiliated Hospital of Qingdao UniversityQingdaoKínaToboroz
Department of Endocrinology, ZhongShan Hospital, Fudan UniversityShanghaiKínaToboroz
Department of Endocrinology, the Eighth Affiliated Hospital, Sun Yat-sen UniversityShenzhenKínaToboroz
Department of Endocrinology, the First Affiliated Hospital of Soochow UniversitySuzhouKínaToboroz
Department of Metabolic Diseases and Weight Management, Weifang People's HospitalWeifangKínaToboroz
Department of Endocrinology, the First Affiliated Hospital of Wenzhou Medical UniversityWenzhouKínaToboroz
Department of Endocrinology, Renmin Hospital of Wuhan UniversityWuhanKínaToboroz
Department of Endocrinology, the Second Affiliated Hospital of Wannan Medical UniversityWuhuKínaToboroz
Department of Endocrinology and Metabolism, Xijing Hospital, Air Force Medical UniversityXi’anKínaToboroz
Department of Endocrinology, Xuzhou Central HospitalXuzhouKínaToboroz
Department of Endocrinology, the First Affiliated Hospital of Henan University of CMZhengzhouKínaToboroz
Department of Endocrinology, the Affiliated Hospital of Zunyi Medical UniversityZunyiKínaToboroz

Te vagy a koordinátor? Erősítsd meg az adatokat

Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.